From the Black Death to the COVID-19 pandemic, combining the genetic data of a pathogen with historical records, archaeological artifacts and epidemiological studies can uncover its origins.
Articles on Biogen
Displaying all articles
Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.
FDA approval of aducanumab (Aduhelm) was contentious. Its submission to Health Canada for approval highlights concerns about evidence, independence and transparency in Canada’s drug approval process.
The new drug is based on the idea that a build-up of amyloid in the brain leads to the disease. But that hypothesis has been under scrutiny lately.
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
After the failure of multiple drug trials the outlook for an Alzheimer’s drug is bleak. This shouldn’t be a surprise. We don’t know the cause or even how to diagnose the disease.
Protein tangles have been blamed for causing Alzheimer’s – but drugs that target them keep failing.
Top contributors
-
Assistant Professor of Emergency Medicine, Albert Einstein College of Medicine
-
Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
-
Associate professor, Department of Family and Community Medicine, University of Toronto; York University, Canada; University of Sydney
-
Professor of Medicine, Dartmouth College
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of cognitive pharmacology, Université du Québec à Montréal (UQAM)
-
Senior Lecturer in Cell Biology, University of Lancashire
-
Professor of Chemistry, Connecticut College